

JFW PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 3589

Serial No.: 10/786,850

Group Art Unit: 1646

Filed: February 24, 2004

Examiner: TBA

For: Novel Subtilases

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Transmittal of Certified Copy of Priority Application(s)
- 2. Certified Copy of Priority Application(s)
- 3. IDS
- 4. IDS SB08
- 5. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to the indicated above on July 2, 2004.

Else-Marie Ulderup

(name of person mailing paper)

(signature of person mailing paper)

Eli leane Mas

forney Docket No.: 10203.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Svendsen et al.

Confirmation No: 3589

Serial No.: 10/786,850

Group Art Unit: 1646

Filed: February 24, 2004

Examiner: TBA

For: Novel Subtilases

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application, or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,

Date: July 2, 2004

Elias J. Lambirs/Reg. No. 33,728 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Unber the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

λ	Sullatute for form 1449A/PTO			
ML 0 6 20		STATEME	TION DISCLOSURE NT BY APPLICANT ny sheets as necessary)	
	Sheet	1	of	

2

Compl	ete if Known
Application Number	10/786,850
Filing Date	February 24, 2004
First Named Inventor	Svendsen et al.
Art Unit	1646
Examiner Name	TBA
Attorney Docket Number	10203.204-US

U.S PATENT DOCUMENTS					
Examiner Initials	Cite No. 1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	_				
			- <u> </u>		
_					
		 			
					

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code ³ – Number ⁴ – Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т 6
		WO 92/17577	10-15-1992	Novo Nordisk A/S	16	
						_
	_					
						<u> </u>
	<u> </u>					
	-					-
	 					
	<u> </u>					
<u> </u>	ļ					
 	 		 			
						

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

10203.204-US

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/786,850 Filing Date February 24, 2004 INFORMATION DISCLOSURE First Named Inventor Svendsen et al. STATEMENT BY APPLICANT Art Unit 1646 (use as many sheets as necessary) **Examiner Name** TBA

Attorney Docket Number

2

of

Sheet

2

	T 0:4-	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title	
Examiner's Initials	Cite No. 1	of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T²
-		R. J. SIEZEN ET AL., The superfamily of sibtilisin-like serine proteases, Protein Science, 1997, pp. 501-523	
		S. DAVAIL ET AL., Purification, Characterization, and Sequence of the Heat-Labile Subtilisin from the Antarctic Psychrophile Bacillus TA41, The Journal of Biological Chemmistry, 1994, pp. 1748-1753, Vol. 269, No 26	
	-	E. NARINX ET AL., Subtilisin from psychrophilic antarctic bacteria: characterization and site-directed mutagenesis of residues possibly involved in the adaptation to cold, Protein Engineering, 1997, pp. 1271-1279, Vol. 10, No. 11	
		K. MIYAZAKI ET AL., Directed Evolution Study of Temperature Adaptation in a Psychrophilic Enzyme, J. Mol. Biol., 2000, pp. 1015-1026, Vol. 297	
-		P.L. WINTRODE ET AL., Cold Adaptation of a Mesophilic Subtilisin-like Protease by Laboratory Evolution, The Journala of Biological Chemistry, 2000, pp. 31635-31640, Vol. 275, No. 41	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.